MCL1, regulated by survival pathways like PI3K/AKT and ERK, is frequently amplified in solid tumors (e.g., non-small cell lung cancer (NSCLC), breast cancer, melanoma) and hematologic malignancies, playing a key role in therapy resistance [26,27,28]. This evidence concerns the gene MCL1 and hematologic disorder.